Sternal neoplasm

Researchers are testing a new cell therapy called CAR001 in adults with solid tumors that have come back or stopped responding to standard treatment. CAR001 uses donor gamma-delta T cells engineered with a chimeric antigen receptor to recognize and attack cancer cells. The trial …

This study tests a personalized vaccine created from a patient's own immune cells (dendritic cells) that are trained to attack unique markers on their tumor. It is for people with advanced solid tumors who have not responded to standard treatments. The main goal is to check safet…

Researchers are testing an experimental biologic called AWT020 in adults with advanced solid tumors that have worsened after at least one standard treatment. The phase 1 trial gives AWT020 every three weeks at increasing dose levels to find the highest dose people can tolerate an…

This early-phase trial tests an experimental drug called HMPL-A580 in 186 adults with advanced or metastatic solid tumors that cannot be removed by surgery. The study aims to find a safe dose and check for early signs that the drug shrinks tumors. It is currently recruiting parti…

This early-phase trial is testing an oral drug called NP-101 in 35 adults with advanced solid tumors that have not responded to standard treatments. The main goal is to check safety and side effects, with a secondary look at whether the drug can shrink tumors. Because it is a Pha…

This early-phase trial is testing an experimental drug called BI-1808, alone or with the immunotherapy pembrolizumab (Keytruda), in people with advanced cancers like ovarian cancer, T-cell lymphoma, and melanoma. The main goals are to check safety, find the best dose, and see how…

This early-phase trial is testing whether combining the drug talazoparib with one of three other drugs (palbociclib, axitinib, or crizotinib) can safely help control advanced solid tumors that have spread. Talazoparib blocks cancer cells from repairing their DNA, while the other …

This Phase 1 trial tests D3L-002, a new drug that targets two immune checkpoints (TIGIT and PVRIG) to help the immune system fight cancer. It is for 24 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the r…

This early-stage trial is testing a new drug called DS3610a in about 70 adults with advanced or metastatic solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can help control the cancer. P…

This early-phase study is testing an experimental drug called YL217 in 220 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the best dose, and look for early signs that the drug can shrink tumors. Participa…

This early-phase study is testing an experimental drug called 177Lu-IM-3050 in adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety and find the best dose. About 105 participants will receive the drug to s…

This study tests a new drug, TER-2013, in people with advanced solid tumors (like breast, ovarian, or lung cancer) that have specific genetic changes in the AKT/PI3K/PTEN pathway. The goal is to see if the drug is safe and can shrink tumors. About 205 participants will receive th…

Researchers are running a first-in-human Phase 1 trial of HG381, an experimental drug given by intravenous injection, in adults with advanced solid tumors that have worsened after available treatments. The study aims to find out how safe and tolerable the drug is, how the body pr…

This study tests a new drug called GI-108 in people with advanced or metastatic solid tumors, including lung, head and neck, pancreatic, and kidney cancers. The drug is designed to boost the immune system's ability to fight cancer. The trial will first find the safest dose, then …

This early-stage study tests a new drug called N-3C01, given alone or with an immunotherapy, in people with advanced solid tumors that have spread or cannot be removed. The main goals are to check safety, find the right dose, and see if the combination shrinks tumors. About 114 a…

This study tests a new drug called WJB001 combined with various chemotherapy drugs in people with advanced solid tumors that have not responded to standard treatments. The trial has three stages to find the safest dose, check how the body processes the drug, and see if it shrinks…

Researchers are testing an experimental injection called SHR-7787 in adults with advanced solid tumors that cannot be removed by surgery or have spread. The trial aims to find a safe dose, measure how the body processes the drug, and look for early signs that it shrinks tumors. P…

Researchers are testing a new oral drug called DC05F01 in adults with recurrent ovarian cancer and other advanced solid tumors that have worsened after standard treatment. The trial aims to see how well the drug shrinks tumors, how long it keeps cancer from growing, and what side…

This study is testing an experimental oral drug called ATX-295 in people with advanced solid tumors, including ovarian cancer, that have not responded to standard treatments. The main goal is to find a safe and tolerable dose and to see if the drug can shrink tumors. About 90 par…

This phase 2 trial tests a drug called BMS-986504 in people with advanced solid tumors that have lost a gene called MTAP. The drug is given alone or with other cancer medicines. The study aims to see if the drug shrinks tumors and how safe it is. About 260 adults will take part.

This early-phase trial tests a new drug called Aza-TdC in adults with advanced solid tumors that have worsened after standard treatment or have no effective therapy. The drug is taken by mouth in 21-day cycles and aims to reactivate genes that may slow tumor growth. The main goal…

This study tests an experimental oral drug called S241656 (BDTX-4933) in people with advanced solid tumors that have certain genetic changes (KRAS, BRAF, or other RAS/MAPK mutations). The trial has two parts: first, finding a safe dose, then testing how well it works alone or wit…

This study tests the immunotherapy drug atezolizumab in 200 people with advanced solid tumors (breast, lung, GI, and others). Researchers use each person's tumor DNA to see if it predicts a response. Participants get the same dose every 3 weeks. The goal is to see if DNA analysis…

This early-stage trial is testing a new oral drug called ISM6331 in 100 adults with advanced mesothelioma or other solid tumors that have not responded to standard treatments. The study aims to find a safe dose and check for any early signs that the drug can shrink tumors. Partic…

This early-stage trial is testing an experimental drug called TQB6426 in people with advanced cancers that have not responded to other treatments. TQB6426 is designed to seek out a protein called GPC3 on cancer cells and deliver a chemotherapy-like payload directly to them. The s…

This study has two parts. Part A tests whether cancer patients who stopped a type of immunotherapy (checkpoint inhibitors) due to side effects can safely restart treatment with durvalumab, given alongside the steroid prednisone to reduce the risk of side effects returning. Part B…

This study provides continued access to dabrafenib and/or trametinib for up to 100 patients with melanoma, lung cancer, or other solid tumors who were benefiting from these drugs in a prior Novartis or GSK trial. The main goal is to track long-term side effects and safety over ti…

This early-stage trial tests a new drug called DXP-106 in 54 people with advanced solid tumors that have not responded to standard treatments. The study aims to find safe doses and see if DXP-106 works better when given alone or with chemotherapy. Participants receive the drug by…

This early-stage study tests a new drug called QLC5508 in 48 adults with advanced solid tumors that have stopped responding to treatment. The main goals are to check if the drug affects heart rhythm, compare two versions of the drug, and see how it interacts with other medicines.…

This early-phase trial tests a new drug called BI 3810944 in adults with advanced solid tumours or melanoma who have no other treatment options. The study aims to find a safe and tolerable dose, and to see if the drug can shrink tumours. Participants receive the drug every three …

This study tests a new oral drug called ART6043, alone or with another drug (olaparib), in 181 people with advanced or metastatic solid tumors. The goal is to check safety, how the body processes the drug, and whether it can slow tumor growth. It is an early-stage trial, so the m…

This study tests an oral drug called zongertinib in adults with advanced solid tumors that have HER2 mutations or overexpression and have not responded to prior treatment. Participants take one of two daily doses and continue as long as they benefit. Doctors regularly check tumor…

This early-stage trial is testing a new drug called BGB-58067, alone or with other cancer treatments, in people with advanced solid tumors that have a specific genetic change (MTAP deficiency). The study aims to find the safest dose and see if the drug can shrink tumors. About 52…

This early-phase study is testing a new drug called BGB-26808, either alone or with another drug (tislelizumab), in people with advanced solid tumors that have not responded to standard treatments. The main goal is to find a safe dose and check for side effects. About 217 partici…

This early-phase trial is testing a new drug called BG-C0902 in people with advanced solid tumors that have not responded to standard treatments. The drug is designed to attach to two proteins (EGFR and MET) often found on cancer cells and deliver a toxic payload directly to them…

This early-phase study tests a new drug, BG-C477, in about 310 people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. The study is open-label, meaning ev…

Researchers are testing an experimental radioactive drug called 177Lu-FAP-VG11 in people with advanced solid tumors that have not responded to standard treatments. The drug is designed to seek out and attach to a protein called FAP, which is found on many tumor cells. This early …

This early-stage trial is testing an experimental oral drug called HW221043 in adults with advanced solid tumors who have no standard treatment options left. The study has two parts: first, finding a safe dose, then expanding to see if the drug can shrink tumors or slow their gro…

Researchers are testing an experimental intravenous biologic called M1-c6v1 in adults with locally advanced or metastatic solid tumors that have not responded to standard treatment. The Phase I trial gives escalating doses to a small group of participants to check safety, find th…

This early-phase study tests a new drug called BG-T187, a special antibody that targets two proteins (EGFR and MET) on cancer cells. It is given alone or with other drugs to people with advanced solid tumors that have spread or cannot be removed. The main goals are to check safet…

This early-phase study tests a new targeted therapy called MK-8294 in people with advanced solid tumors that have spread. The main goals are to check the drug's safety, see if people can tolerate it, and find the highest safe dose. About 67 participants will receive the drug, and…

This study tests a new drug called SKB118 in 332 adults with advanced solid tumors that have not responded to standard treatments. The drug is given by IV every three weeks. The trial will first find the safest dose, then check if it can shrink tumors. It is currently not recruit…

This study is testing a new experimental drug called BG-75098, given alone or with other medicines, in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tum…

This early-stage trial is testing a new biologic drug, GEN1106, in about 103 people with advanced solid tumors, including bladder cancer. The study has three parts: first, finding a safe dose; then refining it; finally, checking how well the drug shrinks tumors. All participants …

Researchers are running a Phase I trial of VRT106, an experimental biological therapy given by intravenous drip, in adults with locally advanced or metastatic solid tumors that have not responded to standard treatment. The trial enrolls about 12 people aged 18 to 75. It aims to f…

This early-stage trial tests the safety of a new drug called KK2269, given alone or with chemotherapy (docetaxel), in adults with advanced solid tumors that have no standard treatment options. About 101 participants will take part. The study has two parts: first testing KK2269 al…

This early-phase study tests a new drug called FORX-428 in about 40 adults with advanced solid tumors that have certain gene changes (like BRCA1/2 mutations). The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors or slow their growth. …

This study is testing a new drug called MK-3120 in people with advanced solid tumors that have spread and cannot be removed by surgery. The main goal is to see if the drug is safe and tolerable. About 270 participants will receive the drug by IV infusion. The study also looks at …

This study tests an experimental drug called SHR-4610 in 258 adults with advanced solid tumors that have stopped responding to standard treatments or have no standard options. The trial has two phases: first, finding the safest dose, and second, checking how well the drug shrinks…

This trial is testing an experimental drug called SA53-OS in people with advanced or metastatic solid tumors that have not responded to standard treatments. The drug works by blocking a protein called MDM2, which may help slow or stop tumor growth. The study has two parts: first,…

This study tests whether adding the immunotherapy drug durvalumab to standard chemotherapy can help control advanced solid tumors that have spread. About 115 adults whose cancer has worsened after at least one prior treatment will receive the combination. The main goal is to chec…

This early-stage trial is testing a new antibody called GEN1079 in people with certain advanced solid tumors. The study has three parts: first, finding a safe dose; then refining the dose; and finally, checking if the drug shrinks tumors. About 121 participants will receive the a…

Researchers are running a phase I/IIa trial of SGT003, an experimental intravenous drug, in adults with advanced solid tumors that have not responded to standard treatments. The study has two parts: a dose-escalation phase to find a safe dose and a dose-expansion phase to look fo…

This phase 1 trial is testing a new drug called ADCE-T02 in people with advanced solid tumors that have not responded to standard treatments. The drug is an antibody-drug conjugate designed to target a protein called tissue factor found on many cancer cells. The main goals are to…

This early-stage trial tests AGX101, a drug that delivers chemotherapy directly to cancer cells by targeting a protein called TM4SF1. About 80 adults with advanced solid tumors (like breast, prostate, or pancreatic cancer) who have run out of standard options will receive the dru…

This trial investigates a new drug called GEN1119 for people with certain solid tumors that have not improved with standard treatments or for whom no standard treatment exists. The study is divided into parts: first, to find safe and effective doses, then to test those doses in m…

This early-phase trial is testing a new experimental drug, BNT317, in 39 people with advanced solid tumors who have run out of standard treatment options. The main goal is to check the drug's safety, find the right dose, and see how the body handles it. It is too soon to know if …

This early-stage study is testing a new drug called M0324, a bispecific antibody designed to target cancer cells. The trial will look at M0324 alone, with the immunotherapy pembrolizumab, and with chemotherapy in about 77 people with advanced solid tumors that have not responded …

This early-stage study tests a new drug called LOXO-783 in people with advanced breast cancer or other solid tumors that have a specific change in the PIK3CA gene. The main goals are to find the safest dose and check for side effects. About 193 participants will take the drug alo…

This early-phase trial tests a new drug called FID-022 in 24 adults with advanced solid tumors that have not responded to standard treatments. The main goal is to find a safe dose and check for side effects. The drug contains two active components, including irinotecan, which is …

This trial tests whether combining bexmarilimab with nivolumab can help people whose cancers no longer respond to immunotherapy. It focuses on two cancers: non-small cell lung cancer and melanoma. The study first finds the safest dose of bexmarilimab to give with a fixed dose of …

This study tests an experimental oral drug called GS-1206 in adults with advanced or metastatic solid tumors that have a specific genetic mutation. The main goals are to evaluate the drug's safety, tolerability, and how the body processes it. Participants must have tumors that ha…

This early-stage trial tests a new drug called SI-B036, a bispecific antibody designed to fight advanced gastrointestinal and other solid tumors. The study involves about 16 adults with tumors that have spread or cannot be removed. Researchers aim to find a safe dose and see if t…

This trial tests an experimental drug called ODM-216 in adults with advanced solid tumors, which are cancers that have spread or cannot be removed by surgery. The study has two parts: the first finds a safe dose, and the second checks how well that dose fights the cancer. Researc…

This early-stage study tests an experimental drug called IMGS-001 in about 105 people with advanced solid tumors that have come back or not improved after standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors. The study has two parts: first, t…

This early-phase study tests a daily oral drug called CGT4255 in 100 adults with advanced solid tumors that have ERBB2 genetic changes or HER2 overexpression. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors, including in the brain. The …

This extension study follows people with von Hippel-Lindau (VHL) disease or advanced solid tumors who are already taking belzutifan in another trial. The goal is to see how long they live and how safe the drug is over the long term. About 450 participants will take belzutifan by …

This study tests an experimental drug called SKB565 in 180 adults with advanced solid tumors that have not responded to or cannot tolerate standard treatments. The trial has three stages to find the safest dose, check how the drug moves through the body, and see if it shrinks tum…

This early-stage trial tests a new drug called VBC101 in people with advanced solid tumors that have stopped responding to standard treatments. The drug is designed to attach to two cancer-related targets (EGFR and cMET) and deliver a toxic payload directly to cancer cells. The s…

This Phase 2 trial tests an oral drug called BAY 2927088 (sevabertinib) in about 111 adults with advanced solid tumors that have HER2 gene mutations. The drug aims to block the abnormal HER2 protein and stop cancer growth. Participants take a 20 mg tablet daily in 3-week cycles u…

This phase 2 trial tests an oral drug called lirafugratinib in 30 adults with advanced solid tumors (excluding bile duct cancer) that have an FGFR2 gene fusion or rearrangement. Participants take the drug regularly and visit the clinic for checkups. The main goal is to see if the…

This study tests a new drug called IPN01203 in about 102 adults with advanced solid tumors that have spread and stopped responding to immunotherapy. The trial has two parts: first, finding a safe dose, then testing low versus high doses to see if the drug can shrink tumors. Parti…

This study tests a new drug called BNT326, given alone or with other cancer immunotherapies, in about 980 adults with advanced solid tumors that have spread or come back after prior treatment. The goal is to find the best dose and see if it is safe and effective. It is an early-s…

This early-stage trial tests an experimental drug called MRTX1719 in adults with advanced solid tumors that have a missing MTAP gene. The study aims to find a safe dose and see if the drug can shrink tumors or slow their growth. About 336 participants with cancers like mesothelio…

This phase I/II platform trial tests several drug combinations, including evorpacept, trastuzumab deruxtecan, zanidatamab, tucatinib, and TTX-MC138, in people with advanced solid tumors, especially metastatic breast cancer. The goal is to find safe and promising regimens that cou…

This early-phase study tests a new drug called DS5361b, alone or with another drug (pembrolizumab), in adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. Ab…

This early-phase trial tests a new drug called NEOK001 in people with advanced solid tumors that have stopped responding to standard treatments. NEOK001 is designed to deliver a cancer-killing agent directly to tumor cells by targeting two specific proteins. The study will first …

The TAPUR study is testing a wide range of targeted cancer drugs in people with advanced solid tumors, lymphoma, or multiple myeloma whose tumors have specific genetic changes. The goal is to see if matching drugs to these genetic variants can shrink tumors or stop them from grow…

This early-stage study tests a new treatment called NT-175 for people with advanced solid tumors (like lung, colon, or breast cancer) that have a specific mutation (TP53 R175H) and a certain immune marker (HLA-A*02:01). NT-175 is made from a patient's own immune cells, which are …

This study tests a new drug called IMA402 in people with advanced solid tumors that have come back or not responded to treatment. IMA402 is designed to help the immune system attack cancer cells. The trial will check if the drug is safe and whether it can shrink tumors.

This trial tests a new drug called VBC108 in people with advanced solid tumors that have not responded to standard treatments. VBC108 is designed to attach to two specific proteins (CLDN18.2 and CDH17) found on some cancer cells and deliver a toxic payload to kill them. The study…

This study tests a drug called eflapegrastim in 40 children with solid tumors or lymphoma who are receiving chemotherapy. The drug aims to boost white blood cells and reduce the risk of serious infections. Researchers are checking how safe it is and how the body processes it.

This study tests a new drug called IPN01195 in about 85 adults with advanced solid tumors that have spread and no longer respond to standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors. Participants must have certain genetic changes in their …

This study tests a new way to give the drug rilvegostomig as a shot under the skin instead of through an IV. It is for adults with advanced solid tumors who have already tried standard treatments. The goal is to find a dose that works as well as the IV version and to check for si…

This early-phase trial is testing a new immunotherapy called LEU011 for people with advanced solid tumors that have not responded to other treatments. LEU011 uses the patient's own immune cells, modified to better recognize and attack tumor cells. The study aims to find a safe do…

This early-stage study tests a new drug called casdatifan (AB521) alone or combined with other cancer drugs in people with advanced clear cell kidney cancer or other solid tumors. The main goals are to check safety and find the right dose. About 362 participants will take part.

This early-stage trial is testing an investigational drug called CX-801, alone or with the immunotherapy Keytruda, in 121 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and find the right dose. Researchers will…

This study tests a new drug, FZ-AD004, for the first time in people with advanced solid tumors that have spread or cannot be removed. The goal is to find a safe dose and see if it can shrink tumors. About 121 adults aged 18 to 75 will take part.

This early-stage study tests a chemotherapy drug (JNJ-1761981) that is injected directly into tumors in people with solid cancers that have not responded to standard treatments. The goal is to find a safe and effective dose, and to see if adding an immunotherapy (cetrelimab) help…

This study is testing an experimental drug called LM-2417, given alone or with other cancer drugs, in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see early signs of tumor shrinkage. …

This early-phase study tests a virus (JNJ-87704916) that is injected directly into tumors to kill cancer cells. It is being tested alone and with another drug (cetrelimab) in people with advanced solid tumors who have run out of standard treatments. The main goals are to check sa…

This early-phase study tests a new drug called BL-B01D1 in people with advanced stomach or other solid tumors that have not responded to standard treatments. The main goals are to find a safe dose and check for any side effects. About 96 adults aged 18 to 75 will take part, and r…

This early-phase trial is testing a modified salmonella bacteria, called SGN1, in 70 people with advanced solid tumors that have not responded to standard treatments. The bacteria are designed to grow inside tumors and release an enzyme that breaks down methionine, an amino acid …

This study tests a modified salmonella bacteria (SGN1) injected directly into tumors. The bacteria are designed to grow inside tumors and cut off their food supply (an amino acid called methionine), causing the tumors to shrink. The trial involves about 70 adults with advanced so…

This early-phase study tests a new drug called ARC101 in 70 people with advanced solid tumors that have a specific marker (Claudin 6). The main goals are to check safety, find the right dose, and see if the drug can shrink tumors. Participants must have ovarian, testicular, or ot…

This early-stage trial tests an experimental drug called E303 in people with advanced solid tumors that have not responded to standard treatments. The drug is designed to target and attack cancer cells while sparing healthy ones. The main goals are to check safety and see if the …

This early-phase study is testing a modified virus called OTS-412, given alone or with hydroxyurea and the immunotherapy atezolizumab, in 27 adults with solid tumors that have stopped responding to standard treatments. The main goal is to check safety and side effects, while also…

This early-phase trial is testing whether a new drug called ORB-021 is safe and tolerable for people with advanced solid tumors who have no standard treatment options left. About 36 adults will receive the drug through an IV to find the best dose for future studies. The main goal…

This early-stage trial is testing an experimental drug called ONO-7429 in about 80 people with advanced or recurrent solid tumors that have not responded to or cannot tolerate standard treatments. The main goal is to find out whether the drug is safe and tolerable, and to determi…

This trial is testing a new drug called DS1025a in people with advanced solid tumors that have spread, cannot be removed by surgery, or have stopped responding to other treatments. The main goals are to check the drug's safety, how the body processes it, and whether it shows any …

This early-stage trial is testing a new drug called lunresertib, alone or combined with two other experimental drugs (RP-3500 and Debio 0123), in people with advanced solid tumors that have not responded to standard treatments. The study aims to find safe doses and check for earl…

This early-phase study tests an experimental drug called VAX014, which is injected directly into tumors to kill cancer cells. It is for adults with advanced solid tumors that have not responded to standard treatments. The study will first find a safe dose of VAX014 alone, then te…

This trial is testing an investigational drug called SHR-A2102, given alone or with other anti-tumor therapies, in people with advanced solid tumors. The goal is to find a safe and effective dose and see how well it shrinks tumors. Participants must be adults with certain types o…

This early-stage trial tests a new drug called SHR-4685 in people with advanced solid tumors that have not responded to other treatments. The main goals are to check the drug's safety, find the best dose, and see how the body processes it. About 170 adults aged 18 to 75 with meas…

This early-stage trial tests a new type of immunotherapy where a patient's own T cells are genetically engineered to recognize and attack cancer cells with a specific KRAS G12D mutation. The study includes adults with advanced lung, colorectal, pancreatic, or endometrial cancers …

This trial is testing whether two experimental oral drugs, APG-115 and APG-2575, can help people with neuroblastoma or other solid tumors that have returned or not responded to standard treatment. The study will first find the safest dose, then expand to see how well the drugs wo…

This early-phase trial is testing an experimental biologic drug, DBC-664, in adults with advanced solid tumors such as ovarian, lung, and stomach cancers that have spread or come back. The study has two parts: first, finding a safe dose, and then expanding to see how well the dru…

This early-stage study tests a new drug called HH160 in about 56 adults with advanced solid tumors (cancers that have spread). The main goals are to check safety, find the best dose, and see if the drug shrinks tumors. Participants will receive HH160 alone or with other cancer tr…

This early-stage study tests a new drug (177Lu-DOTA-SNA040) that delivers radiation directly to cancer cells with a specific marker (Claudin 18.2). It is for people with advanced stomach, pancreatic, or bile duct cancers that have worsened after standard treatment. The main goals…

This early-phase trial tests a new drug called YKYY031 in 76 people with advanced solid tumors (like colorectal or pancreatic cancer) that have stopped responding to standard treatments. The main goals are to check safety, find the right dose, and get a first look at whether the …

This study tests an experimental daily pill called REC-1245 in people with advanced solid tumors or lymphomas that have not responded to or are not eligible for standard therapies. The main goals are to find a safe dose and check if the drug can shrink tumors. About 170 adults wi…

This study tests a personalized vaccine made from a patient's own tumor proteins, given alone or with the immunotherapy drug pembrolizumab. The goal is to see if the combination is safe and helps the immune system attack advanced solid tumors. About 132 people with various advanc…

This early-phase study tests a new drug called SIM0689 in adults with advanced solid tumors that have stopped responding to standard treatments. SIM0689 is a bispecific antibody designed to block two cancer-promoting pathways (PD1 and VEGF). The trial will first find a safe dose,…

This early-stage trial is testing an experimental drug called HS-20117-2 in people with advanced solid tumors. The main goals are to understand how the drug behaves in the body, check its safety, and see how well people tolerate it. Participants receive the drug as a subcutaneous…

This study tests an experimental drug called Tulmimetostat (DZR123) in people with advanced solid tumors or lymphomas that have not improved with standard treatments. The drug is taken as a daily pill, either alone or combined with another drug (enzalutamide) for certain prostate…

This study tests an experimental therapy called GT201, made from a patient's own immune cells (tumor-infiltrating lymphocytes), for advanced solid tumors. About 18 adults will receive the treatment to see if it is safe and can shrink tumors. The goal is to control the disease, no…

This trial is investigating whether spatially fractionated radiotherapy, a technique that delivers radiation in a grid-like pattern, can safely and effectively treat bulky (larger than 4 cm) or refractory solid tumors. The study will measure how many patients complete the treatme…

This study tests a new drug called AI-081 in people with advanced solid tumors that have spread or cannot be removed by surgery. The drug is a bispecific antibody that targets two proteins (PD-1 and VEGF) involved in cancer growth and immune evasion. The trial has two phases: fir…

This early-stage study tests a new oral drug, APR-1051, in about 90 adults with advanced solid tumors that have not responded to other treatments. The main goals are to check the drug's safety and find the right dose. Researchers will also look for early signs that the drug might…

This early-stage trial is testing an investigational drug called GIM-122 in adults with advanced solid tumors that have not responded to standard treatments, including PD-1/PD-L1 inhibitors. GIM-122 is a special antibody designed to fight cancer in two ways. The study aims to fin…

This study tests whether adjusting common over-the-counter medications can make immune checkpoint inhibitors work better for people with solid tumors. Participants are asked to avoid acetaminophen and cannabis/THC/CBD, while taking aspirin and loratadine (or similar antihistamine…

This early-phase trial is testing an experimental oral drug called GIM-531, alone or with an immunotherapy (anti-PD-1), in 117 adults with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if the drug is safe, tolerable, and can help th…

This early-stage trial tests a new drug called CS5007 in people with advanced solid tumors that cannot be removed by surgery. The drug is designed to seek out and attack cancer cells while sparing healthy ones. The study will first find the safest dose and then check if the drug …

This early-stage study tests a new tablet called GW01-200 in 100 people with advanced solid tumors or blood cancers that have stopped responding to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. Participan…

This study is the first time the drug BNT3214 is being tested in people. It aims to find a safe and effective dose for adults with advanced solid tumors. The trial has three parts: first, finding the best dose; then, testing it in different cancer types. About 533 participants wi…

This early-stage study tests a new drug called JL19001 in people with advanced solid tumors or a type of lymphoma that has come back or not responded to treatment. The main goal is to find a safe dose and check for side effects. About 14 participants will receive the drug as a sh…

This early-stage trial is testing an experimental drug called MBS8(1V270), given alone or with the immunotherapy pembrolizumab, in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and find the right dose. About 1…

This trial tests several cancer drugs in children and young adults with solid tumors. It uses a master protocol to test different drug combinations more efficiently. About 105 participants will receive one of eight drugs, including ramucirumab, cyclophosphamide, and others. The g…

This trial is testing an investigational drug called ARV-6723, given as a pill, in people with advanced solid tumors. The drug is designed to help the immune system recognize and attack cancer cells. The study will test ARV-6723 alone and in combination with pembrolizumab, an imm…

This early-phase study tests a new drug called BG-C0979, alone or with another drug (tislelizumab), in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. Ab…

This trial is testing an experimental therapy called STX-003, which uses mRNA to produce a protein that may help the immune system fight cancer. It is given intravenously, either alone or with the immunotherapy drug pembrolizumab (Keytruda). The study involves adults with advance…

This study tests a new drug called zanzalintinib, alone or with other immune-boosting drugs, in people with advanced solid tumors that have stopped responding to standard treatments. The goal is to find safe doses and see if the combination can shrink tumors or slow their growth.…

This trial tests an experimental drug called KLS-1, a form of zinc aspartate enriched with a specific zinc isotope, in adults with certain solid tumors (like melanoma, prostate, or pancreatic cancer) or chronic lymphocytic leukemia (CLL). The goal is to find the safest and most e…

This early-stage trial is testing an experimental immunotherapy called AB122, given alone or combined with other investigational drugs, in people with advanced solid tumors such as pancreatic, colorectal, lung, and stomach cancers. The goal is to find out which combinations are s…

This trial investigates whether tumor-infiltrating lymphocytes (TILs) — immune cells taken from a patient's own tumor — can be expanded in the lab and infused back to attack cancer. It enrolls adults aged 18 to 75 with advanced solid tumors who have failed standard treatments. Th…

This early-phase trial is testing a personalized cancer vaccine (ABO2109) combined with an immunotherapy drug (toripalimab) in people with solid tumors. The vaccine is custom-made for each patient to target their specific cancer. The study aims to check the safety of this combina…

This study tests a new drug called LM-168 combined with other cancer treatments (tislelizumab or docetaxel) in 108 adults with advanced solid tumors. The first part finds a safe dose; the second part checks if the combination shrinks tumors. It is not yet recruiting.

This study tests a new drug called PM54 combined with the immunotherapy pembrolizumab in adults with advanced cancers that have not responded to prior treatments. The goal is to find a safe dose and see if the combination can shrink tumors or stop them from growing. About 119 par…

This early-stage trial tests a new daily pill called TYRA-430 in 100 adults with advanced liver cancer or other solid tumors that have specific genetic changes. The main goals are to find the safest dose and check for side effects. Researchers will also look for signs that the dr…

This early-phase study tests an experimental drug called ZE94-0605 in about 60 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to find a safe dose and check for any signs of tumor shrinkage. The study is not yet recruiting.

This early-phase trial is testing an experimental drug called ROSE12, alone or combined with other anti-tumor agents, in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to evaluate safety, determine the best dose, and look…

This phase 3 trial is testing an experimental drug called VC004 in people aged 12 and older with advanced or metastatic solid tumors that cannot be removed by surgery. The goal is to see whether VC004 capsules can shrink tumors and control the disease. All participants receive th…

This trial tests a new drug called N17350, a modified enzyme injected directly into tumors, in adults with advanced solid tumors that have not responded to standard treatments. The study aims to find the safest and most effective dose, and to see if the drug can shrink or stop tu…

This large trial tests whether a structured program called RESET can improve outcomes for adults undergoing planned cancer surgery. RESET combines pre-surgery preparation (prehabilitation), enhanced in-hospital recovery practices, and personalized support after discharge. Researc…

This study tests a new drug called LCB02A for people with advanced solid tumors that have a specific marker (CLDN18.2) and haven't responded to standard treatments. The drug is designed to deliver a toxin directly to cancer cells. The trial has two phases: first, finding the safe…

This early-stage trial is testing an experimental oral drug called ISM8207 in people with advanced solid tumors or relapsed/refractory B-cell lymphoma who have no standard treatment options left. The main goals are to check the drug's safety, tolerability, and how the body proces…

This early-phase trial is testing an experimental drug called M3T01, a monoclonal antibody that targets a protein called FasL, in people with advanced solid tumors that have spread or cannot be removed by surgery. The study aims to see if M3T01 is safe and tolerable when given al…

This early-stage trial is testing a new drug called IBI3028 in people with advanced solid tumors that cannot be removed by surgery or have spread. The drug works by attaching to two proteins (EGFR and c-Met) found on some cancer cells and delivering two anti-cancer agents directl…

This trial is testing an experimental drug called AT-1965 in people with advanced solid tumors that have stopped responding to standard treatments. The study has two parts: first, finding a safe dose, and then seeing whether the drug can shrink tumors. About 100 participants will…

This early-phase study tests a new drug called GSK5533524, alone or with other cancer treatments, in adults with advanced solid tumors that have stopped responding to standard therapies. The main goals are to find a safe dose and see if the drug can shrink tumors or slow cancer g…

This study tests a new drug called STK-012, which is designed to boost the immune system's ability to fight cancer. It is being tested alone or with standard treatments (pembrolizumab, pemetrexed, carboplatin) in people with advanced solid tumors, especially those with a type of …

This early-stage trial tests an experimental oral drug called APG-2449, alone or combined with another cancer drug, in people with platinum-resistant recurrent ovarian cancer or other advanced solid tumors. The study aims to find safe doses and understand how the drug works in th…

This early-stage study tests a new drug, AUBE00, in about 90 to 130 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. Participants must have a spec…

This first-in-human study tests an experimental drug called CX-2051, alone or with Avastin, in 160 adults with advanced solid tumors that have worsened after standard treatment. The main goals are to check safety and find the right dose, while also looking for early signs of tumo…

This phase 1 trial tests an experimental drug called ACM-CpG, given as a shot into the muscle, in people with advanced solid tumors that have not responded to standard immunotherapy. The drug is designed to activate the immune system to attack tumors. The study aims to find the s…

This phase 1 trial tests an experimental drug called PA5 in adults with advanced solid tumors that have not responded to standard treatments. PA5 is designed to break down arginine, an amino acid some cancers need to grow. The study aims to find the safest dose and check for side…

This early-phase trial is testing an experimental therapy called WTX-212C, which uses specially engineered red blood cells to treat advanced solid tumors. The study will enroll 24 adults whose cancer has not responded to standard treatments. The main goal is to check safety and f…

This study tests an experimental drug called LRK-4189, given alone or with standard chemotherapy, for adults with advanced solid tumors that have not responded to prior treatment. The main goal is to check the drug's safety and find the best dose. About 120 participants will take…

This study tests an experimental therapy called YH02, a genetically modified virus designed to infect and destroy cancer cells. It is given as an injection directly into tumors in people with advanced solid tumors (such as head and neck cancer, breast cancer, or melanoma) that ha…

This study tests a new drug called ICP-B208 in about 539 people with advanced solid tumors that cannot be removed by surgery or have spread. The main goals are to check the drug's safety, find the best dose, and see if it shrinks tumors. Participants must be 18-75, have failed pr…

This study tests a new oral drug called NXP900 in people with advanced solid tumors (like lung, kidney, or mesothelioma) that have not responded to standard treatments. The trial has two parts: first, finding the right dose, and then seeing if the drug shrinks tumors. It is a fir…

This study tests targeted cancer drugs in people with advanced solid tumors that have not responded to standard treatments. Participants receive a drug chosen based on the genetic changes in their tumor. The goal is to see if the treatment can stop or shrink the cancer for at lea…

This study tests a program where clinical pharmacists provide personalized counseling to cancer patients taking oral anticancer drugs. The goal is to see if this support helps patients take their medication more consistently. Researchers will compare two groups of 80 patients eac…

This study tests a new drug called STX-478 in people with advanced solid tumors that have a specific genetic change (PI3Kα mutation). The trial has two phases: first, it tests STX-478 alone to find safe doses; then, it combines STX-478 with other cancer drugs like fulvestrant or …

The DETERMINE trial is testing whether drugs already approved for some cancers can help people with rare cancers or common cancers that have rare genetic mutations. It will enroll 825 adults, teenagers, and children whose cancers have specific DNA changes. The goal is to find new…

This early-phase study tests a new drug called PYX-201 in people with advanced solid tumors that have come back or spread. The main goals are to find a safe dose and see if the drug can shrink tumors. About 330 adults with certain breast, head and neck, or other cancers are being…

This study tests a new drug called HRS-4508 in combination with other cancer treatments (such as capecitabine, trastuzumab, and pertuzumab) for people with advanced solid tumors that cannot be removed by surgery or have spread. The goal is to find the best dose, check safety, and…

This early-phase trial tests a new oral drug called IPG7236 combined with the immunotherapy toripalimab in adults with advanced solid tumors that have spread or cannot be removed. The study has two parts: first, finding the safest dose of IPG7236, then expanding to see if the com…

This Phase 2 trial is testing a combination of three drugs—gemcitabine, mitomycin C, and thalidomide—given in low, frequent doses to people with advanced solid tumors that have not responded to prior treatments. The goal is to see if this approach can slow tumor growth and improv…

This early-stage trial tests a new oral drug called SNV1521 in 400 people with advanced solid tumors that have spread. The main goals are to check safety, find the best dose, and see if it can shrink tumors. Researchers will also test SNV1521 combined with other cancer drugs.

This early-stage trial tests a new drug called ONC-841 in people with advanced solid tumors that have spread. The drug is an antibody designed to help the immune system attack cancer cells. The study will first find a safe dose, then test it alone and with standard treatments for…

This study tests an experimental oral drug called NTS071 in adults with advanced solid tumors that have a specific change in the TP53 gene (Y220C mutation). The trial has two parts: first, finding a safe dose, and then checking if the drug can shrink tumors. About 220 people who …

This early-stage trial tests an experimental drug called mocertatug rezetecan in 675 adults with advanced solid tumors that have not responded to standard treatments. The drug is designed to deliver a toxin directly to cancer cells. The main goals are to check safety, find the ri…

This phase 1 trial tests an experimental drug, DXC006, in people with advanced solid tumors (like small cell lung cancer and neuroblastoma) or blood cancers (like multiple myeloma) who have not responded to standard treatments. DXC006 is an antibody-drug conjugate designed to del…

This early-phase trial is testing a new drug called H1710 in 36 adults with advanced solid tumors who have no standard treatment options left. The main goal is to check the drug's safety, find the right dose, and see how the body processes it. Researchers will also watch for any …

This phase 1 trial tests whether specially designed viruses (VSV-based oncolytic viruses) can safely treat advanced solid tumors that have not responded to standard treatments. The viruses are injected into the body to infect and destroy cancer cells. The study focuses on safety …

This phase 1 trial tests a new therapy called MSK-TCR5 for people with advanced solid tumors that have a specific genetic change (RAS G12D mutation) and a certain immune type (HLA-A*11:01). The therapy uses a patient's own T-cells, modified in a lab to better recognize and attack…

This early-phase study is testing a new drug called OVV-01 in 18 people with advanced solid tumors that have not responded to standard treatments. The drug is given either through a vein or directly into a tumor. The main goal is to check safety and find the right dose, while als…

This early-stage study tests a new drug called STP938 in 70 adults with advanced solid tumors that cannot be cured by current treatments. The main goal is to check safety and find the right dose. The study also looks at how the drug moves through the body and includes a special g…

This study looks at the long-term safety and benefits of the drug pelabresib in people with blood cancers, solid tumors, or advanced cancers. It includes up to 50 adults who were in earlier pelabresib studies and are still benefiting from the drug. Some participants who received …

This early-stage trial tests a new drug called AN8025 in about 91 adults with advanced solid tumors that have not responded to standard treatments. The main goal is to find a safe dose and check for side effects. Participants receive the drug in 3-week cycles and are closely moni…

This phase 2 trial tests a new radiation technique called SBRT-LATTICE-PATHY for people with large tumors (at least 7 cm or 340 cm³) that cannot be treated with standard methods. The approach delivers a high dose of radiation only to low-oxygen areas inside the tumor, aiming to i…

This study tests a new treatment using a patient's own immune cells, called CAR T cells, that are specially designed to target and kill solid tumor cells while leaving healthy cells unharmed. It is for adults with certain advanced cancers, including lung, colon, pancreatic, ovari…

This early-stage trial tests a new drug called KO-2806, alone or with other cancer drugs, in adults with advanced solid tumors that have not responded to standard treatments. The study aims to find safe doses and check for early signs of tumor shrinkage. About 300 participants wi…

This study tests a new treatment made from specially engineered immune cells (T cells) donated by healthy people. The cells are designed to better recognize and kill cancer cells while lasting longer in the body. The trial includes 24 adults with blood cancers or solid tumors tha…

This study tests a new drug called IAH0968, given alone or with chemotherapy (CAPEOX), in people with advanced HER2-positive stomach cancer or other solid tumors. The goal is to see if the combination is safe and helps slow cancer growth better than standard treatment. About 574 …

This early-stage trial is testing an experimental drug called HS-20108 in 502 people with advanced solid tumors that have spread or cannot be removed. The main goal is to find a safe dose and check for side effects. Researchers will also look for any signs that the drug might shr…

This early-stage trial tests a new drug called SIM0613 in about 294 adults with advanced solid tumors that have worsened after standard treatments. The study has two parts: first, finding a safe dose, then expanding to see if the drug shrinks tumors. The main goals are safety and…

This study tests a new drug called UI-102, which is a tiny nanoparticle designed to activate the immune system to fight cancer. It is for people with advanced solid tumors that have not responded to standard treatments. The trial will enroll 140 participants to first find the saf…

This early-phase study is testing a new biologic drug called JLM019 in adults with advanced solid tumors or lymphomas that have come back or not responded to treatment. The drug is given as a weekly intravenous infusion, and the main goals are to check its safety, find the right …

This study tests an experimental drug called RMC-9805, taken as a pill, in adults with advanced solid tumors (such as lung, colorectal, or pancreatic cancer) that have a specific mutation in the KRAS gene called G12D. The drug is given alone or in combination with another oral dr…

This early-phase study tests a new drug called RC220 given with the chemotherapy doxorubicin in adults with advanced solid tumors that cannot be removed by surgery or have spread. The main goals are to find a safe dose and see if RC220 can protect the heart from doxorubicin's sid…

This study tests an experimental drug called INV-6452 in adults with advanced breast cancer (HR+/HER2-) or other solid tumors that have stopped responding to standard treatments. The goal is to find the safest dose and see if the drug can shrink tumors. About 201 participants wil…

This early-phase study tests a new drug called CT3001 in people with advanced solid tumors (like colorectal or pancreatic cancer) that have stopped responding to standard treatments. The study has two parts: first, finding a safe dose of CT3001 alone, then testing it combined wit…

This study looks at how the cancer drug ASTX727 (decitabine and cedazuridine) works in people with moderate or severe liver problems. About 27 adults with certain blood cancers or solid tumors will take the drug for up to 8 weeks. The goal is to understand how the liver affects t…

This early-stage study looks at how the body handles the cancer drug ASTX727 (decitabine and cedazuridine) in people with severe kidney problems compared to those with normal kidneys. It includes 18 adults with acute myeloid leukemia, myelodysplastic syndromes, or solid tumors. T…

This early-phase study tests whether spending time in a cool room (around 18°C for 12 hours a day) can make standard immunotherapy drugs work better for people with solid tumors. Twenty-four adults with various solid cancers will receive cold exposure alongside their usual PD-1/P…

This early-stage trial tests a new drug called HLX316 in people with advanced solid tumors that have not responded to standard treatments. The drug is designed to help the immune system attack cancer cells. The study will check for safety, side effects, and whether the drug can s…

This study tests a new drug, ALK201, for the first time in people with advanced solid tumors that have not responded to other treatments. The goal is to find a safe dose and see if the drug can shrink tumors. About 202 adults aged 18 to 75 will take part. The study is currently r…

This early-stage trial is testing a new drug called Risvutatug rezetecan (Ris-Rez) in people with advanced solid tumors that have spread or cannot be removed. The study will give Ris-Rez alone or combined with other cancer drugs like chemotherapy or immunotherapy. Researchers wan…

This study tests a new experimental drug called mavrostobart (PT199) in people with advanced solid tumors, specifically non-small cell lung cancer and pancreatic cancer. The drug is given alone or combined with other cancer treatments. The goal is to find the safest dose and see …

This early-stage trial is testing a new drug, QLS5212, in 100 people with advanced solid tumors that cannot be removed by surgery or have spread. The drug is an antibody-drug conjugate designed to deliver a cancer-killing agent directly to tumor cells. The main goals are to find …

This early-phase study is testing a new treatment called KXV01 for people with advanced solid tumors, including sarcomas, who have no other options. The therapy uses a patient's own immune cells, modified with a virus to recognize and attack their specific tumor. The main goal is…

This study tests a new drug, SKB103, in people with advanced solid tumors who have run out of standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors or slow their growth. About 277 adults aged 18 to 75 will take part.

This early-phase trial tests AMT-676, a drug designed to seek out and destroy cancer cells that carry a protein called CDH17. It is given intravenously to 24 adults with advanced solid tumors (such as colorectal, gastric, or pancreatic cancer) that have not responded to prior tre…

This study tests a new treatment for people with solid tumors that have come back or not responded to standard care. The treatment uses a patient's own immune cells (T-cells) that are genetically modified in a lab to recognize and attack a protein called PRAME found on cancer cel…

This study tests a mix of five oral drugs (hydroxychloroquine, metformin, sirolimus, dasatinib, and nelfinavir) in people with advanced solid tumors or prostate cancer that has come back. The goal is to find the safest dose and see if the combination can stop the cancer from grow…

This early-phase trial is testing a new drug called IUAb190708, an antibody designed to attack cancer cells by targeting a protein called PD-L1. The study involves 90 adults with advanced or recurrent solid tumors who have run out of standard treatment options. The main goal is t…

This early-phase study is testing a new drug called PEEL-224 in 65 people with advanced solid tumors that have not responded to standard treatments. The main goals are to find a safe dose and check for side effects. Researchers will also look for signs that the drug can shrink tu…

This early-stage trial tests whether injecting specially reprogrammed immune cell particles (exosomes) directly into tumors is safe for people with advanced solid tumors who have run out of standard options. Nine adults aged 18-65 will receive four injections over eight weeks. Th…

This study tests a new drug called SHR-9839, given with other cancer treatments, for people with advanced solid tumors that have not responded to standard therapy. The goal is to see if the combination is safe and can shrink tumors. About 156 adults aged 18-75 with certain cancer…

This study tests a drug called romiplostim N01 in children, adolescents, and young adults (ages 6-24) with cancer who develop low platelet counts from chemotherapy. The drug is given as a weekly shot to help the body produce more platelets. The goal is to see if it can safely and…

This study tests a new drug, ODM-212, in about 315 adults with advanced solid tumours that cannot be cured with current treatments. The trial has two parts: first finding a safe dose, then testing that dose in more people. The main goal is to check for side effects and see how th…

This study tests a new drug called DT-7012, alone or with another cancer drug (an immune checkpoint inhibitor), in 125 adults with advanced solid tumors that have not responded to prior treatments. The goal is to see if the combination is safe and can shrink tumors. It is an earl…

This study tests a modified herpesvirus (T3011) combined with standard immunotherapy drugs (PD-1/PD-L1 inhibitors) in people with advanced solid tumors that have not responded to other treatments. The goal is to see if the combination is safe and can shrink tumors. About 68 parti…

This study tests a new drug called MDX2001 in people with advanced solid tumors that have spread. The main goals are to check the drug's safety and see if it can shrink tumors. About 285 adults with various cancers like lung, breast, or colon cancer will take part. This is an ear…

This early-phase trial is testing a new treatment called NK521 for people with advanced solid tumors that have spread and caused fluid buildup in the belly (malignant ascites). The treatment uses a person's own natural killer (NK) cells that have been gene-edited to better attack…

This study tests a new drug called CKD-703 in people with advanced solid tumors or non-small cell lung cancer that has a specific protein (c-Met). The drug is designed to attach to cancer cells and release chemotherapy directly inside them, aiming to kill the cancer while reducin…

This early-phase trial is testing whether a specially designed bacteria, CMTS1215, can safely shrink solid tumors. About 20 adults with advanced solid tumors who have no other treatment options will receive the bacteria directly into their tumor or through a vein. The main goals …

This early-phase study tests a new drug called AM-928, given as an IV infusion, in about 38 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to find the safest dose and understand side effects. Researchers will also look for ear…

This study tests an experimental oral drug called NBM-BMX in people with advanced solid tumors or newly diagnosed glioblastoma (a type of brain cancer). The drug is given alone for solid tumors or combined with standard treatments (radiation and chemotherapy) for brain cancer. Th…

This study tests an experimental drug called REGN10597, alone or with another drug (cemiplimab), in people with advanced solid tumors like melanoma and kidney cancer. The goal is to see if the treatment is safe and can shrink tumors. About 240 participants will receive the drug i…

This study tests a new oral drug called HEC169096 in people with advanced solid tumors, including thyroid cancer and non-small cell lung cancer, that have a specific RET gene change. The trial has two phases: the first finds the safest dose, and the second checks how well the dru…

This phase 2 trial tests a new radiation technique called lattice radiation therapy (LRT) combined with immunotherapy in 30 people with advanced solid tumors that have not responded to standard treatments. LRT delivers high doses of radiation to small spots inside the tumor while…

This early-phase study tests a new drug called IMC-002 in about 62 adults with advanced solid tumors that no longer respond to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can help control the cancer. Participants receive t…

This phase 2 trial is testing valemetostat, a daily pill, in 900 adults with advanced solid tumors that have specific gene changes (like SMARCB1 or ARID1A). The drug works by blocking EZH1/2 enzymes to reactivate genes that normally protect against cancer. The main goal is to see…

This study tests a drug called toripalimab, which helps the immune system fight cancer, in people with advanced solid tumors that have specific genetic changes (POLE or POLD1 mutations) and have not responded to standard treatments. The trial aims to see if the drug can shrink tu…

This study looks at two ways to trigger ovulation in women with cancer who are freezing their eggs before chemotherapy. One method uses a GnRH agonist alone, the other combines it with hCG (dual trigger). The goal is to see which approach retrieves more eggs while reducing the ri…

This early-stage trial is testing a new drug called GS-2121, taken as a tablet, alone or with an intravenous drug called zimberelimab, in 154 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the best dose, …

This early-stage trial is testing a new drug called HS-20110 in 475 adults with advanced solid tumors that have not responded to standard treatments. The study aims to find a safe dose and see if the drug can shrink tumors. Participants receive HS-20110 by IV infusion in 21-day c…

This early-stage study tests a new drug called HDM2024 in 63 people with advanced solid tumors that have not responded to standard treatments. The main goals are to check if the drug is safe and to see if it can shrink tumors. Participants receive the drug once every three weeks,…

This early-phase study tests an experimental oral drug called NST-628 in adults with advanced solid tumors that have specific genetic changes in the MAPK pathway. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. About 230 partic…

This study tests a new drug called XNW28012 in people with advanced solid tumors (pancreatic, ovarian, cervical, or colorectal cancers) that have stopped responding to standard treatments. The trial has two parts: first, finding a safe dose, then expanding to see if the drug shri…

This study tests an experimental drug called PRL3-zumab in 52 adults with advanced solid tumors. The drug is given by IV every two weeks. Researchers want to see if it can slow cancer growth and how safe it is. Participants must have had no more than three prior treatments and be…

This early-stage trial is testing a new drug called ATG-022 in people with advanced or metastatic solid tumors that have not responded to standard treatments. The main goal is to find a safe dose and check for side effects. Up to 156 participants will receive the drug every three…

This phase IIa trial is testing two experimental drugs, HX009 and IN10018, given together with or without standard chemotherapy, in 124 adults with advanced solid tumors, specifically biliary tract cancer and melanoma. The study aims to find the best dose and see if the combinati…

This early-phase trial is testing a new approach to CAR-T cell therapy for adults with advanced solid tumors that have not responded to standard treatments. The therapy uses a patient's own immune cells, engineered to recognize two cancer-specific targets chosen based on each per…

This early-stage trial tests a genetically modified version of the Yersinia enterocolitica bacterium, given alone or with the immunotherapy pembrolizumab, in 100 adults with advanced solid tumors that have no standard treatment options. The goal is to find a safe dose and see if …

This early-stage trial is testing an oral drug called HQP1351 in about 100 people with advanced gastrointestinal stromal tumors (GIST) or other solid tumors. The main goal is to find a safe dose and see how the body handles the drug. Participants take the pill every other day for…

This study tests a new treatment using donor immune cells (CAR-NK cells) that are engineered to recognize and attack cancer. The treatment is personalized based on a tumor's unique markers. It is for adults with advanced solid tumors that have not responded to other therapies. Th…

This early-stage trial is testing NK042, a ready-made natural killer cell therapy made from healthy donors, in 76 people with advanced solid tumors that have not responded to standard treatments. Participants first receive chemotherapy to prepare their immune system, then an infu…

This early-phase trial is testing an experimental drug called DB-1310 in 1000 adults with advanced solid tumors that have worsened after standard treatments. The study aims to find a safe dose and check for early signs of tumor shrinkage. It is a first-in-human study, so the main…

This study tests two experimental drugs, QLP2117 and QL2107, given together to people with advanced solid tumors that have not responded to standard treatments. The goal is to find a safe dose and see if the combination can shrink tumors. About 149 participants will be enrolled i…

This early-stage study is testing a new oral drug called CS23546 in about 156 adults with advanced solid tumors or lymphoma that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see how the body processes it. Resear…

This early-phase trial is testing an investigational drug called SYS6043 in adults with advanced or metastatic solid tumors that have spread or no longer respond to standard treatments. The study aims to find a safe dose and watch for side effects, while also looking for early si…

This early-phase study tests a new oral drug, TSL2109, in people with advanced solid tumors, especially prostate and breast cancers that have stopped responding to standard treatments. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors o…

This early-stage trial is testing a new treatment called VET3-TGI, a virus designed to infect and destroy cancer cells. It is being given alone or with the immunotherapy drug atezolizumab to 60 people with advanced solid tumors that have not responded to standard treatments. The …

This study tests whether eating low-protein meals (10% protein instead of the usual 20%) can boost the immune system's response to immunotherapy in cancer patients. Researchers will enroll 30 adults with solid tumors that have spread. The main goal is to see if patients can stick…

This study tests a new drug called HRS-8364 in people with advanced solid tumors that have not responded to standard treatments. The trial has three stages to find the safest dose and check how well the drug shrinks tumors. About 282 participants will take part across multiple ce…

This early-phase study tests an experimental drug called WJB001 in people with advanced solid tumors who have no standard treatment options left. The trial has three parts: first, finding a safe dose; second, checking how well that dose works; and third, testing it in specific tu…

This early-stage trial is testing a new daily oral medication called ETX-19477 in about 120 adults with advanced solid tumors, including breast, ovarian, prostate, and other cancers. The drug blocks a protein called PARG to interfere with cancer cells' ability to repair themselve…

This study is testing whether combining two drugs—Envafolimab (an immunotherapy injection) and Lenvatinib (a daily pill)—can shrink tumors in people with advanced solid cancers like lung, kidney, and liver cancer. About 170 adults whose cancer has worsened after standard treatmen…

This phase 2 trial is testing Envafolimab, an immunotherapy drug given as a shot, in 126 adults with advanced solid tumors that have not responded to standard treatments. The study aims to see if patients with a high number of tumor mutations respond better than those with fewer …

This phase 2 trial is testing an immunotherapy drug called KN035, given as a shot under the skin, for people with advanced solid tumors that have specific genetic features (dMMR or MSI-H). The study includes 200 participants with colorectal cancer or other solid tumors who have a…

This study tests a drug called trilaciclib to protect bone marrow in people with solid tumors receiving chemotherapy. The goal is to reduce severe drops in blood cells, which can be dangerous and delay treatment. Researchers will build a model to predict who benefits most from th…

This study tests a new treatment called Enhanced ALPP CAR-T cells for people with advanced solid tumors that have not responded to standard therapies. The treatment involves taking a patient's own immune cells, modifying them in a lab to recognize and attack cancer cells that hav…

This early-stage study tests an experimental pill called ABSK021 in people with advanced solid tumors (including a rare joint tumor called TGCT) who have run out of standard options. The main goal is to check safety and find the best dose, while also seeing if the drug can shrink…

This study tests whether two experimental drugs, AK119 and AK112, can safely shrink or control advanced solid tumors that have stopped responding to standard treatments. About 87 adults with various solid tumors will receive the drug combination. The main goals are to check safet…

This early-stage trial is testing an engineered mitochondrial vaccine in 12 people with advanced solid tumors who cannot have standard treatments. The vaccine is given as a series of shots to see if it is safe and can help control the cancer. The study focuses on safety first, wi…

This early-phase trial is testing an experimental drug called INV-1120, either by itself or combined with the immunotherapy pembrolizumab (Keytruda), in adults with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find safe doses an…

This early-stage study is testing a new two-part immune therapy for people with advanced solid cancers like stomach, colon, or pancreatic cancer. The treatment combines special dendritic cells that guide the immune system to the tumor with CAR-T cells that directly attack cancer …

This study tests whether dapagliflozin, a drug used for diabetes, can prevent kidney damage caused by platinum-based chemotherapy in people with solid tumors. About 46 participants will receive either dapagliflozin or a placebo for a few days around their chemo session. Researche…

This study tests a new drug called ABSK141 in people with advanced solid tumors that have a specific gene change called KRAS G12D. The goal is to find a safe dose and see if the drug can shrink tumors. About 401 adults with cancers like colorectal, lung, or pancreatic cancer will…

This phase 2 trial is testing a daily pill called JAB-21822 (Glecirasib) in 88 people with advanced pancreatic cancer or other solid tumors that have a specific KRAS G12C mutation. Participants must have already tried standard treatments without success. The main goal is to see i…

This study is testing two experimental drugs, 7MW3711 and JS207, given together (with or without chemotherapy) in people with advanced solid tumors that have stopped responding to standard treatments. The trial has two phases: first, finding the safest dose, then checking how wel…

This early-stage study tests a new drug called tolododekin alfa (ANK-101) for people with advanced solid tumors that have not responded to standard treatments. The drug is injected directly into the tumor to see if it is safe and tolerable. About 97 adults with various solid canc…

This study tests a new drug called JK06, designed to seek out and attack cancer cells while sparing healthy ones. It is for adults with advanced solid tumors that cannot be removed by surgery or have spread. The main goals are to find the safest dose and see if the drug can shrin…

This study tests a combination of two drugs, MCLA-129 and ensartinib, in people with advanced solid tumors that cannot be cured. The drugs work by blocking certain proteins that help cancer grow. The trial has two phases: first to find the safest dose, then to see if the combo sh…

This early-stage study tests a new drug called Hemay181 in 24 people with advanced solid tumors that have not responded to standard treatments or have no standard options. The main goal is to see if the drug can shrink tumors and to check for side effects. Participants will recei…

This pilot study tests whether giving precise, high-dose radiation to all visible tumors (up to 10) can improve the effectiveness of immunotherapy in people with advanced solid tumors that have spread. About 28 adults with 3-10 metastases will receive radiation over 3 weeks while…

This early-phase trial tests a new drug called CDR404 in up to 42 adults with advanced solid tumors that have a specific marker (MAGE-A4) and tissue type (HLA-A*02:01). The drug is designed to help the body's immune T-cells find and attack cancer cells. The main goals are to chec…

This study tests a new drug called CNSI-Fe(II), which is injected directly into tumors. It uses iron to trigger a type of cell death called ferroptosis, aiming to control advanced solid tumors like lung, pancreas, and colorectal cancers. The trial involves 54 adults whose current…

This early-stage trial tests a new type of immunotherapy for children and young adults with solid tumors that have not responded to standard treatments. The therapy uses the patient's own immune cells, which are genetically modified in the lab to recognize and attack cancer cells…

This study tests a new drug called SYS6043 in people with advanced or metastatic solid tumors that have not responded to standard treatments. The drug is an antibody-drug conjugate designed to target and kill cancer cells. The trial will first find the safest dose, then expand to…

This study tests a new approach using immune cells from healthy donors, engineered to recognize and attack cancer cells. The target is chosen based on each participant's tumor profile. The trial includes 85 adults with advanced solid tumors that have not responded to standard tre…

This study tests whether giving radiation early to spine tumors that are not yet painful can prevent serious problems like fractures or spinal cord compression. About 74 adults with cancer that has spread to the spine will receive radiation before symptoms get worse. The goal is …

This study tests a new treatment called EBNK-001, made from donor immune cells (natural killer cells), in people with advanced solid tumors that have not responded to standard therapies. Participants receive the cells after chemotherapy to prepare the body, along with low-dose in…

This early-phase trial tests a new drug called RPTR-1-201 in 150 adults with advanced solid tumors that cannot be cured with standard treatments. The drug works by helping the body's immune cells attack cancer. The study aims to find the safest dose and see if the drug shrinks tu…

This early-stage study tests the drug pralatrexate in 24 adults with advanced cancer and varying levels of liver function. The goal is to see how the body processes the drug and to find the right dose for people with mild, moderate, or severe liver impairment. Participants receiv…

This study is testing an experimental drug called MCLA-129 in people with advanced solid tumors, including non-small cell lung cancer, head and neck cancer, and colorectal cancer. The drug is a bispecific antibody designed to attach to two cancer-related proteins (EGFR and c-Met)…

This study compares two different dosing schedules of the blood thinner apixaban (Eliquis) against no blood thinner in about 996 cancer patients at moderate risk for blood clots. Participants take either 2.5 mg twice daily, 5 mg once daily, or no anticoagulant for 6 months. The g…

This phase 2 trial is testing whether adding a special type of radiation called adaptive pulse radiotherapy to standard immunotherapy can help treat advanced solid tumors. The study will enroll 35 people who are already receiving or planning to receive immune checkpoint inhibitor…

This early-phase trial is testing a new drug called TGI-5, given alone or with the immunotherapy nivolumab, in people with advanced solid tumors such as colorectal, liver, lung, and skin cancers. The study aims to find safe doses and check for side effects in about 194 participan…

This early study tests a new cell therapy called GK01, made from a patient's own immune cells, for advanced solid tumors. Fifteen participants will receive GK01 alone or with chemotherapy after surgery. The main goal is to check safety, not yet to prove it works.

This study tests whether giving radiotherapy early to high-risk bone metastases that are not yet causing symptoms can prevent future bone complications like fractures. About 120 adults with solid tumors and at least three bone metastases will be randomly assigned to either standa…

This study tests a new tablet called ABP1011T in people with advanced solid tumors, including small cell lung cancer and others like esophageal or bladder cancer. Participants take one pill daily in 21-day cycles. The goal is to see if the drug can shrink tumors and how safe it i…

This early-stage trial tests a new drug called ONM-501, which is injected directly into tumors, either alone or with the immunotherapy cemiplimab (Libtayo). The study includes 168 adults with advanced solid tumors or lymphomas that have not responded to standard treatments. The m…

This study tests whether a drug called mecapegfilgrastim can safely prevent moderate-to-severe myelosuppression (low blood cell counts) caused by chemotherapy and radiation for lung or esophageal cancer. About 30 adults aged 18-75 will receive the drug alongside their standard ca…

This early study is testing a new drug called WTX212A, alone or with radiation, in 12 people with advanced solid tumors. The goal is to see if it shrinks tumors and is safe. It's a small first step to find out if this approach is worth studying further.

This study tests a drug called brigatinib in children and young adults (ages 1 to 25) with certain ALK-positive cancers, including anaplastic large cell lymphoma and inflammatory myofibroblastic tumors. The goal is to find the best dose and see how safe and effective the drug is.…

This early-stage study tests a new drug called ERAS-4001 in people with advanced solid tumors that have certain KRAS mutations. The main goal is to see if the drug is safe and find the best dose, either alone or with other treatments. About 200 adults who have no good standard op…

This study tests whether a fecal microbiota transplant (FMT) combined with the immunotherapy drug nivolumab can help people with advanced solid cancers that stopped responding to prior treatment. About 50 participants will receive the combination to see if it can shrink tumors. T…

This trial is testing two drugs, vemurafenib and cobimetinib, already approved for melanoma, in adults with other rare cancers that have a specific genetic change called BRAF V600 mutation. The goal is to see if the combination can shrink tumors or stop them from growing. About 3…

This study tests a new radioactive drug called 177Lu-SN201 in people with advanced solid tumors that have not responded to standard treatments. The drug is designed to target tumors using tiny particles. The main goals are to check safety, find the right dose, and see if it can s…

This study tests A2B395, a donor-derived CAR T-cell therapy designed to target cancer cells while sparing healthy ones. It is for adults with advanced solid tumors like colorectal, lung, or breast cancer that have lost a specific immune marker. The trial has two phases: first to …

Researchers at Erasmus Medical Center are testing whether a fluorescent imaging agent can highlight cancer cells on the surface of tumor tissue removed during surgery. The study involves 200 adults with solid tumors who are scheduled for surgery. After the tumor is removed, the d…

This study tests a new PET scan that uses a special tracer to find a protein called CLDN18.2 on solid tumors. The goal is to see if this scan can help identify which patients might benefit from treatments that target this protein. About 15 adults with solid tumors will receive th…

This trial is testing two new PET imaging tracers, FAPI-RuiJ and FAPI-04, to see how well they detect, stage, and monitor various solid tumors. The study will compare the diagnostic accuracy of these tracers against standard methods in 200 adults with suspected or confirmed tumor…

This trial is testing whether a new PET imaging agent can safely and effectively detect a protein called MMP14 on solid tumors. The study will involve about 30 adults with various solid tumors, such as melanoma, lung, or breast cancer. Each participant will receive the experiment…

This study evaluates a rapid test called Methylscape that measures DNA methylation patterns in body fluids like blood, urine, or saliva. The goal is to see if it can detect a cancer signal and even predict where the cancer started, using a single sample. Researchers will compare …

This phase 1 trial is testing whether a new imaging tracer called 18F-TRX can safely and effectively detect solid tumors using PET scans. The tracer targets unstable iron levels, which are often elevated in cancerous tissue. Adults with advanced solid tumors, including certain pr…

This study tests a new imaging agent called F18 FBPA, which is designed to light up cancer cells during a PET/CT scan. The agent targets a protein often found on solid tumors, potentially making tumors easier to see. Researchers want to find the best dose and timing for the scan,…

This study is testing a special MRI scan that uses a unique contrast agent to see how aggressive advanced solid tumors are and how they respond to treatment. About 65 people with advanced solid tumors will get the scan before and during their standard cancer therapy. The goal is …

This study is testing a new blood test that looks for DNA from cancer cells. The goal is to see if an artificial intelligence program can accurately detect many different types of cancer at an early stage. The study will include 6,000 adults, some with cancer and some healthy vol…

This study is testing a new blood test that looks for DNA and protein signals from cancer cells. The goal is to find multiple types of cancer early, before they cause symptoms. Researchers will compare blood samples from 20,000 people with and without cancer to see if the test wo…

This early-stage study tests a single dose of a new radioactive tracer called [68Ga]Ga-R54, which attaches to a protein (CXCR4) found on some cancer cells. Ten adults with advanced solid tumors or multiple myeloma will receive the tracer and then have a PET/CT scan to see where i…

This early-stage trial is testing an injectable dye called NC527-X that may make tumors glow during surgery, helping surgeons see exactly where the cancer is. The study will enroll 400 adults with solid tumors who are already scheduled for surgery. Participants receive one of fou…

This study tests a new imaging probe called 89Zr-s-C1 that attaches to a protein (MUC18) found on some solid tumors. The goal is to see if this PET/CT scan can find tumors that standard scans miss. About 20 adults with newly diagnosed or recurring solid tumors (like melanoma or s…

This study tests a new radioactive tracer called [68Ga]Ga-THP-PDL1-3 for PET/CT scans in 50 adults with solid tumors. The goal is to see if it can safely and accurately show PD-L1 levels in tumors, which may help doctors personalize cancer treatment. Participants will receive bot…

This early-stage study is testing a new radioactive dye called RT01-89Zr that attaches to a protein found on many solid tumor cells. The goal is to see if it can safely and clearly show tumors on PET/CT scans. About 10 adults with advanced solid tumors will receive the dye and be…

This study tests a new radioactive dye called 68Ga-NI-FAPI for PET/CT scans. It aims to better detect diseases like tumors, heart problems, and lung scarring by targeting a protein linked to tissue damage. About 30 people, including healthy volunteers and patients, will take part…

This phase 3 trial tests an experimental drug called REGN7508 to prevent blood clots in people with solid tumors who are receiving cancer treatment. About 1,120 participants will receive either the drug or a placebo. The study measures how well the drug prevents clots and checks …

This phase 2 trial is testing an experimental drug called SIR2501 in adults with solid tumors who are about to receive paclitaxel-based chemotherapy. The goal is to see if SIR2501 is safe, tolerable, and might reduce the development of chemotherapy-induced peripheral neuropathy—a…

This study tests whether a topical oil made from aconite can prevent or reduce nerve damage (polyneuropathy) caused by chemotherapy in cancer patients. About 350 adults with solid tumors receiving taxane or platinum chemotherapy will apply the oil or a placebo to their skin twice…

This study tests whether taking mecobalamin (a form of vitamin B12) can prevent or reduce nerve damage caused by taxane chemotherapy. About 326 adults with various solid tumors will take mecobalamin tablets or receive no preventive treatment during their chemo. The goal is to see…

This study looks at how well the shingles vaccine works in people with weakened immune systems, such as those with cancer or autoimmune diseases. Researchers will measure immune responses and track side effects in 300 adults. The goal is to see if the vaccine can effectively prev…

This phase 3 trial compares lattice radiation therapy (LRT) to standard radiation for reducing pain from large solid tumors (at least 5 cm). About 148 adults whose tumors cannot be surgically removed will be randomly assigned to one of the two radiation approaches. The main goal …

This study tests if the drug ustekinumab can control diarrhea and colon inflammation caused by immune checkpoint inhibitors in cancer patients. Ten adults with solid tumors who have moderate to severe symptoms will receive ustekinumab and be monitored for side effects and symptom…

This phase 2 trial at MD Anderson Cancer Center is testing whether psilocybin-assisted psychotherapy can safely help ease depression and anxiety in 30 adults with advanced cancer who are on maintenance therapy. Participants receive either psilocybin or a placebo (niacin) along wi…

This trial tests whether duloxetine, a drug commonly used for depression, can reduce the painful nerve damage that some cancer patients experience after receiving taxane chemotherapy. The study enrolls adults with solid tumors who have at least moderate pain from this side effect…

This study adapts a counseling program called Meaning Centered Psychotherapy for Latinos with advanced cancer. The goal is to improve spiritual well-being and quality of life. Researchers will enroll 190 Latino adults with stage III or IV solid tumors to test the program's feasib…

This early-stage study tests a drug called resiniferatoxin (RTX), a chemical from a cactus-like plant similar to hot pepper, for people with severe cancer pain that standard treatments can't control. RTX is injected into the spine to destroy pain-transmitting nerves. The trial in…

This study looks at whether a noninvasive treatment called whole-body infrared hyperthermia can help people with advanced solid tumors feel better. The therapy uses infrared energy to raise body temperature in a controlled way, and researchers will track changes in pain, fatigue,…

Researchers at Singapore General Hospital are testing whether a one-on-one coaching session, called CONCORD, helps patients with advanced cancer prepare for serious illness conversations with their doctors. The session, led by a trained lay coach, covers topics like understanding…

This study tests whether a telephone coaching program called Talking About Cancer (TAC) helps people with advanced cancer and their support person engage in advance care planning, such as having end-of-life conversations and completing advance directives. About 80 patients and th…

This study tests if eating only within an 8-hour window each day (time-restricted eating) can reduce treatment side effects and improve quality of life for people with solid tumors starting adjuvant therapy after surgery. Fifty adults will be randomly assigned to follow this eati…

This study explores whether a brief behavioral program can help cancer patients and their sleep partners get better rest. The program teaches techniques like limiting time in bed and going to bed only when sleepy, aiming to improve sleep efficiency. Participants, who are couples …

This trial tests whether Yunzhi essence, a mushroom extract from Coriolus versicolor, can improve quality of life for people with advanced cancer. Participants take either the extract or a placebo for six months, while researchers measure changes in well-being, survival, and immu…

This study tests whether modafinil, a drug that promotes wakefulness, can reduce severe fatigue and thinking problems in people with advanced cancer. About 40 adults with stage III or IV cancer will receive either modafinil or a placebo for a short time. The goal is to see if the…

This study tests whether a homeopathic product called Encer can reduce fatigue in people with solid tumors who are starting chemotherapy or radiation therapy. Participants are randomly assigned to receive either Encer or a placebo, and their fatigue levels are tracked using a que…

This phase 2 trial tests whether a combination of olanzapine and ondansetron can prevent nausea and vomiting caused by high-dose cisplatin chemotherapy in people with solid tumors. The approach aims to reduce steroid use by omitting dexamethasone on days 2 through 4. The study en…

This trial investigates whether an online, nurse-guided version of cognitive behavioral therapy (CBT) can reduce severe fatigue in people with advanced cancer who are receiving palliative systemic treatment. Participants complete a 12-week online CBT program with support from the…

This study tests special gloves and boots that gently squeeze the hands and feet during chemotherapy. The pressure may reduce how much chemo reaches the nerves, possibly preventing pain and numbness. About 142 adults with cancer will try the devices to see if they help avoid nerv…

This pilot study tests whether brodalumab, a drug used for autoimmune conditions like psoriasis, can safely reduce immune-related side effects caused by cancer immunotherapy. About 11 adults with advanced solid tumors who developed these side effects will receive brodalumab injec…

This study tests whether a simple card game, the Go Wish Game, can help people with advanced blood cancers or solid tumors discuss their end-of-life priorities with doctors. About 75 patients will use the cards to sort what matters most to them, then complete an advance care plan…

This study tests a special type of radiation called lattice therapy for people with large, hard-to-treat tumors. The goal is to see if it can shrink tumors better than standard radiation and help people feel better. About 37 adults with advanced solid tumors will receive this tre…

This study tests whether playing a serious game on an iPad can help older adults (60+) better manage nausea and vomiting caused by chemotherapy. About 610 participants will be randomly assigned to play the game or receive usual care. Researchers will track symptom severity, quali…

This study tests whether a special cooling cap can prevent hair loss in children receiving chemotherapy for non-cancerous conditions or solid tumors. The cap is worn before, during, and after chemo to keep the scalp cool. Researchers want to see if it is safe and tolerable for 40…

This study compares two approaches to supportive cancer care for nearly 3,000 adults with cancer. One group gets information through email or their health record, while the other works one-on-one with a lay health worker over 12 months. The goal is to see which model better impro…

This study looks at whether a one-day hospital visit that includes medical, psychological, and social support can help teens and young adults (ages 15-25) feel better after finishing cancer treatment. About 214 participants who have completed treatment for a solid tumor or lympho…

This study looks at whether medical hypnosis can help reduce anxiety in people with solid tumors who are getting radiation therapy. About 45 moderately to very anxious patients will either listen to relaxing music alone or combine it with hypnosis during their sessions. The goal …

This study tests whether specially trained nurses can help children with cancer and their families by starting conversations about palliative care early. About 120 children recently diagnosed with cancer will be randomly assigned to either receive these nurse-led talks or standar…

This study tests whether a program of targeted exercise and psychological support before cancer treatment (called prehabilitation) can help patients with solid tumors recover better physically and emotionally. Researchers will compare this program to standard care in 125 adults w…

This study tests whether electronic surveys can help people with advanced cancer report their symptoms and care needs, so their doctors can connect them to palliative (supportive) care services sooner. About 90 adults with incurable solid tumors will participate. The goal is to s…

This study tests whether a cream containing tretinoin (a form of vitamin A) can prevent or reduce the acne-like rash that often occurs in patients taking certain cancer drugs. About 25 adults with advanced solid tumors will apply the cream to one side of their face and a placebo …

This study tests whether urolithin A, a dietary supplement, can improve the immune system's response to standard immunotherapy drugs in people with newly diagnosed solid tumors like lung cancer or melanoma. 45 participants will be randomly assigned to receive either urolithin A o…

This study tests whether remote health education workshops are feasible for adolescents and young adults with cancer. Participants will attend three online sessions designed to help them manage their disease and treatment. The goal is to see if patients stick with the program and…

This study follows over 1,500 children and adults who previously received gene-modified T cell therapy for cancer. Researchers will track side effects, how long the modified cells last, and overall survival for up to 15 years. No new treatment is given—the goal is to understand l…

This study looks at how a cancer drug called pelabresib changes the way the body processes three other medicines: repaglinide (for diabetes), midazolam (a sedative), and a birth control pill. It involves 24 adults with advanced cancers who have no standard treatment options. The …

This early-phase study is testing the cancer drug pelabresib in 24 people with advanced cancers who also have liver problems. The goal is to see how the liver affects the drug levels in the body. Participants will take the drug daily for 14 days, then have a week off. This resear…

This large screening trial enrolls up to 2,900 people with advanced solid tumors that have spread or not responded to standard treatment. Researchers use genetic tests on tumor samples to find specific mutations, then assign patients to treatment trials testing drug combinations …

Cell therapies such as CAR-T and TIL therapy are emerging options for advanced solid tumors, but their benefits are uncertain and side effects can be severe. Researchers at Zhejiang University are surveying about 420 cancer doctors and 600 patients in China to learn how each grou…

This study collects tissue samples from people with solid tumors who are already scheduled for surgery or biopsy at the NIH Clinical Center. Researchers will use the samples to study the biology of cancer and identify new targets for therapy. Up to 1,800 adults and children (age …

This pilot study investigates whether certain molecules in the blood, called miRNAs and proteins, change during cancer treatment and whether these changes can signal early signs of heart or lung damage. Researchers will compare blood samples from patients receiving radiation or c…

This study will collect data from 2,000 patients in the Netherlands and France who are receiving standard, minimally invasive cancer treatments like tumor ablation or catheter-based therapies for liver, lung, kidney, or bone cancers. During these procedures, a special CT scanner …

This study looks at how the way medical information is presented influences treatment choices for people with advanced cancer. About 400 participants will fill out questionnaires and review made-up case scenarios. The goal is to learn how to better communicate health options to e…

This study collects blood samples from people with cancer or at high risk for cancer to create a large, well-organized repository for research. The goal is to provide scientists with a valuable resource to study cancer through liquid biopsies, which may lead to better detection a…

This study is a large registry that collects health information and leftover tumor or blood samples from up to 75,000 children and young adults with cancer. The goal is to track outcomes and gather data to help doctors find better ways to treat and care for these patients over ti…

This study explores whether analyzing the genetic makeup of a tumor biopsy can help identify advanced cancer patients who might benefit from targeted treatments. Adults with solid tumors who have no standard treatment options will have a biopsy of their lesion for molecular profi…

This study follows a large group of children and young adults who received radiation therapy for cancer, to see how their health and quality of life evolve over many years. By collecting medical data and blood samples in a European registry, researchers aim to identify late effec…

This early-stage study tests whether people with advanced solid tumors can safely follow a diet low in methionine, an amino acid found in many proteins. Researchers will measure how well participants stick to the diet, check for side effects, and track changes in blood methionine…

This observational study aims to identify genetic mutations in adults with advanced solid cancers who are being considered for or are already in early-phase clinical trials. By analyzing tumor and blood samples over time, researchers hope to understand how these mutations influen…

This study looks at a standardized method for giving high-dose radiation a second time to people with solid tumors that have come back. It uses advanced imaging to better calculate radiation doses to sensitive organs like the spinal cord and gut. The goal is to track how often se…

This study follows 6,000 adults with solid tumors who are receiving immune checkpoint inhibitors as part of their routine cancer care. Researchers are tracking how long patients live and how long their disease stays under control. The goal is to learn how well these drugs work in…

This study enrolls 1,000 adults with advanced solid tumors that have progressed after standard treatment. Researchers will use genetic tests to match patients to specific drugs, like Alectinib or Atezolizumab, based on their tumor's gene changes. The goal is to see if this person…

This study tracks 770 adults with advanced solid cancers (like lung, head and neck, melanoma, or bladder cancer) who are receiving immunotherapy. Researchers collect tumor and blood samples over time to find biological markers that predict how well the treatment works or causes s…

This study looks at 100 people with advanced solid tumors whose cancer stopped responding to immunotherapy. Researchers will take a fresh tumor sample and blood tests to compare genetic and immune differences between those who never responded and those who initially improved but …

This study is collecting detailed genetic and health information from 500 people with various cancers, including breast, lung, and leukemia. The goal is to create a shared database that helps researchers develop more personalized treatments. Participants provide samples and data,…

This study is looking at special markers in the blood (called biomarkers) to learn more about how to detect, diagnose, and track solid cancers. Researchers will collect blood samples from 6,000 adults with solid cancer and analyze them alongside standard tests. The goal is to see…

This early-phase study tests a new radioactive tracer called [89Zr]DFO-starPEG to see if it can make tumors show up better on PET scans. The goal is to learn how the tracer behaves in the body and whether it can help doctors see the "leakiness" of tumor blood vessels, which may g…

This study follows 600 childhood cancer survivors aged 8-18 to understand why symptoms like fatigue, pain, and depression often occur together. Researchers will use questionnaires and stool samples to see if gut bacteria and their byproducts play a role. The goal is to find bette…

This study aims to collect and analyze tumor samples from 10,000 adults with advanced solid cancers (like breast, lung, or colon cancer) to create a province-wide gene database. The goal is to help doctors identify which targeted drugs or clinical trials might work best for each …

This study analyzes the DNA of solid tumors from 5,500 cancer patients to find genetic changes that could be targeted by specific treatments. The goal is to use this molecular profile to match patients with appropriate clinical trials. Participants must have a confirmed solid tum…

This study is for people with advanced solid tumors who have run out of standard treatment options. Researchers will track how well off-label or non-standard therapies work when chosen based on the tumor's genetic profile. The goal is to create a standard way to measure responses…

This study looks at two ways to help cancer patients preserve their fertility before treatments like chemotherapy. One group will freeze both ovarian tissue and eggs, while the other group will freeze only eggs. Researchers will compare how many eggs are retrieved in each group. …

This study looks at 500 adults having cancer surgery to see which risk scoring system best predicts if they'll need intensive care afterward. Doctors will calculate scores like ASA and SORT from patient data before and during surgery. The goal is to find the most accurate tool to…

This study tests whether using artificial intelligence (AI) to rewrite medical discharge letters into plain language helps cancer patients better understand their diagnosis, treatment, and next steps. About 150 adults with blood cancer or other cancers will be randomly assigned t…

This study enrolls up to 10,000 adults with cancer to see how a special team of experts (a molecular tumor board) uses genetic testing to recommend personalized treatments. Researchers will track whether doctors follow these recommendations and if patients benefit. The goal is to…

This study is collecting information from 1,000 people with solid tumors who receive chemotherapy through a special catheter called RenovoCath, which delivers drugs directly to the tumor site. Researchers are tracking safety, side effects, and survival over time. The goal is to l…

This study is collecting medical data and biological samples from 15,000 people receiving radiation therapy for solid tumors or blood cancers. Researchers aim to understand how radiation affects quality of life, side effects, and survival. The goal is to learn from real-world out…

This study is creating a detailed database of 651 adults with solid tumors who are starting immunotherapy. Researchers will collect medical and lab information over 5 years to see how well these treatments work in everyday practice. The goal is to learn more about outcomes like s…

This study looks at how to set the breathing machine (jet ventilator) during a procedure that destroys tumors with heat or cold. The goal is to find the best air pressure setting to keep patients breathing well while the doctor works precisely. About 560 adults having tumor ablat…

This registry study is collecting data from 2,800 cancer patients treated with ion beam therapy (protons and carbon ions) at MedAustron. Researchers will track tumor response, survival, side effects, and quality of life over time. The goal is to better understand the real-world b…

This study tests a personalized approach for patients with advanced liver or colorectal cancers that no longer respond to standard treatments. Doctors take a small sample of the tumor, grow it in the lab as 3D 'organoids', and test different drugs on them to see which works best.…

This research study collects blood and tissue samples from 20,000 people with suspected solid tumors. The samples are stored in a repository for scientists to study later. The goal is to advance our understanding of cancer, not to test a new treatment.

This study collects blood samples from 1,500 adults, including cancer patients, healthy volunteers, and COVID-19 donors. Researchers aim to develop a device that can grow, select, and test immune cells (T cells) from the blood. The goal is to see if these cells can be trained to …

This study aims to develop a machine learning tool to predict heart damage in 600 cancer patients receiving certain chemotherapy drugs (anthracyclines or HER2-targeted therapies). Researchers will collect data over one year to see who develops heart problems. The goal is to creat…

This study collects tissue samples from people with various advanced or early-stage cancers to train a diagnostic platform called Elephas. The goal is to see how accurately it can predict whether a patient will respond to immunotherapy or chemoimmunotherapy. About 324 participant…

This study is testing whether a blood test that looks for tumor DNA (ctDNA) can find cancer returning earlier than standard scans. About 100 people with different solid tumors will give blood samples after treatment. The goal is to see if early detection can lead to better treatm…

This study will collect blood and tumor samples from 20,000 adults with solid tumors to perform detailed genetic analysis. The goal is to find how many patients have at least one genetic change that could be targeted by existing or experimental therapies. This is a research study…

This study tests whether newer imaging techniques like special ultrasound and MRI can detect heart damage earlier in children, adolescents, and young adults who have had cancer treatment. Researchers will follow 400 participants to see how many develop heart problems. The goal is…

This study is gathering information from 500 cancer patients treated with proton therapy, a type of radiation that may cause fewer side effects than standard radiation. Researchers want to see how well it works in everyday practice and track any side effects. The goal is to build…

This study aims to find immune system markers that can predict how well a cancer patient responds to radiotherapy. Researchers will analyze blood samples from 40 adults who have already completed radiotherapy without major side effects. The goal is to personalize future cancer tr…

This study watches 50 people who already received a replimune oncolytic immunotherapy for cancers like melanoma or liver cancer. The goal is to check for any delayed side effects over 5 years. No new treatment is given—just regular check-ins to see how patients are doing.

This study compares a continuous heart-monitoring patch with standard electrocardiograms (ECGs) in 60 adults receiving cancer drugs that can cause dangerous heart rhythm changes. The goal is to see if the patch detects problems more accurately and consistently. Participants will …

This study aims to find a way to predict which cancer patients will experience side effects from immunotherapy. These side effects happen when the immune system attacks healthy tissues, similar to autoimmune diseases. Researchers will collect blood samples from 300 cancer patient…

This study aims to create a large collection of blood samples from 2,500 people with or at high risk for cancer. Researchers will use these samples to study liquid biopsies, which are blood tests that may help detect cancer, track treatment response, and spot recurrence. Particip…

This study is analyzing tumor and blood samples from 10,000 adults with advanced solid tumors or blood cancers to find genetic changes that can be targeted by existing drugs. The goal is to see how often these 'actionable' alterations occur and to guide patients toward personaliz…

This study will collect blood and tumor samples from 1,100 people with various cancers, including head and neck, ovarian, cervical, lung, and brain cancers. Researchers want to learn how immune cells called T cells behave in these tumors. The goal is to better understand why some…

This study looks at how much protein cancer patients eat before, during, and after radiotherapy, and whether that affects their muscle mass and quality of life. Researchers will track 175 adults aged 45 and older undergoing radiation for various tumors. The goal is to understand …